Belantamab mafodotin
- Generic Name
- Belantamab mafodotin
- Brand Names
- BLENREP
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2050232-20-5
- Unique Ingredient Identifier
- DB1041CXDG
- Background
Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).
...
- Indication
Belantamab mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 35
- Registration Number
- NCT04617925
- Locations
- π«π·
Centre hospitalier Universitaire de Limoges -, Limoges, France
π©πͺUniversity Hospital Heidelberg, Heidelberg, Germany
π¬π·General Hospital of Athens "Alexandra", Athens, Greece
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT04549363
- Locations
- πΊπΈ
GSK Investigational Site, Chapel Hill, North Carolina, United States
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 357
- Registration Number
- NCT04484623
- Locations
- π¬π§
GSK Investigational Site, Plymouth, United Kingdom
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT04398745
- Locations
- πΈπ¬
GSK Investigational Site, Singapore, Singapore
A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT04398680
- Locations
- π°π·
GSK Investigational Site, Suwon-si, Gyeonggi-do, Korea, Republic of
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 494
- Registration Number
- NCT04246047
- Locations
- π¬π§
GSK Investigational Site, Sutton, United Kingdom
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT04177823
- Locations
- π¨π³
GSK Investigational Site, Jiang Su Province, China
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 325
- Registration Number
- NCT04162210
- Locations
- π¬π§
GSK Investigational Site, Plymouth, United Kingdom
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 464
- Registration Number
- NCT04126200
- Locations
- πΈπͺ
GSK Investigational Site, Stockholm, Sweden
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 144
- Registration Number
- NCT04091126
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.